Potential use of terbinafine in the treatment of aspergillosis

Reviews in Contemporary Pharmacotherapy

Volumn 8, Issue 5, 1997, Pages 349-356

  Schiraldi, G F ^a   Colombo, M D ^b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Novartis Prodotti Farmaceutici SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; TERBINAFINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG ASPERGILLOSIS; MALE; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030668786     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-284.
2. Barbareschi M, Vago T, Colombo MD et al. Terbinafine induces the PMNL priming effect and enhances in vitro PMNL fungicidal activity against Candida albicans blastospores. Mycoses 1993; 36: 405-409.
3. Barrett-Bee K, Ryder NS. Biochemical aspects of ergosterol biosynthesis inhibition. In: Sutcliffe JA, Georgopapadakou NH, eds. Emerging targets for antibacterial and antifungal chemotherapy. New York: Chapman and Hall, 1992: 410-436.
4. Basisch J, Graves T, Nasir Baz M et al. Allergic bronchopulmonary aspergillosis in corticosteroid-dependent asthmatics. J Allergy Clin Immunol 1981; 68: 98-102.
5. Bates JH. Amphotericin B. Amphotericin B methylester, and other polyenes. In: Sarosi A, Davies SF, eds. Fungal disease of the lung. New York: Raven Press, 1993: 295-312.
6. Becker JW, Burke W, McDonald G, Greenberger PA, Henderson WR, Aitken ML. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest 1996; 109: 1536-1540.
7. Clayton YM. The in vitro activity of terbinafine against uncommon fungal pathogens. In: Fromtling, RA, ed. Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona: Prous Science Publishers, 1987: 433-439.
8. Currie DC, Lueck C, Milburn MJ et al. Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Thorax 1990; 45: 447-450.
9. De Freitas C, Marote J, Sequeira H, Faria A. Sporotricose cutanee disseminee. Ann Dermatol Venereol 1994; 121 (Suppl 1): 111.
10. Engelkens HJH, Naafs B. Mycetoma. Br J Dermatol 1990; 131: 722-723.
11. Foss NT, Rocha MRO, Lima VTA et al. Entomorphthoramycosis: therapeutic success by using amphotericin B and terbinafine. Dermatology 1996; 193: 258-260.
12. Gefter WB, Weingrad TR, Epstein DM et al. 'Semi-invasive' pulmonary aspergillosis. A new look at the spectrum of Aspergillus infections of the lung. Radiology 1981; 140: 313-321.
13. Goodman NL, Roberts GD. General mycology. In: Sarosi A, Davies SF, eds. Fungal disease of the lung. New York: Raven Press, 1993: 1-16.
14. Harari S, Schiraldi GF, de Juli E et al. Is terbinafine an alternative treatment for noninvasive aspergillus bronchitis in lung transplanted recipients? Eur Respir J 1996; 9: 367.
15. Henderson AH, Pearson JE. Treatment of bronchopulmonary aspergillosis with observation on the use of natamycin. Thorax 1968; 23: 519-523.
16. Howard J, Schwartz E, Greenberger PA. The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk. J Lab Clin Med 1991; 117: 138-142.
17. Hull PR, Vismar HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol 1992; 126: 51-55.
18. Iber C. Allergic bronchopulmonary fungal disease. In: Sarosi A, Davies SF, eds. Fungal disease of the lung. New York: Raven Press, 1993: 205-214.
19. Jones TC. Clinical study report on use of SF 86-327 in systemic mycoses. Data on file, Sandoz Document 0603-223. Basel: Sandoz, 1988.
20. Lee KH, Kim YS, Chung HS, Park K. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. Transpl Proc 1996; 28: 1488-1489.
21. Odds FC. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother 1993; 31: 463-471.
22. Patterson R, Greenberger PA, Halwig JM et al. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986; 146: 916-918.
23. Pennington JE. Aspergillus. In: Sarosi A, Davies SF, eds. Fungal disease of the lung. New York: Raven Press, 1993: 133-147.
24. Roberts GD, Goodman NL. The diagnostic clinical mycology laboratory. In: Sarosi A, Davies SF, eds. Fungal disease of the lung. New York: Raven Press, 1993; 17-28.
25. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 (Suppl 39): 2-7.
26. Ryder NS, Leitner I. Activity of terbinafine against Aspergillus in vitro, in combination with amphotericin B or triazoles. Abstract E54. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 15-18 September, 1996. Washington: American Society for Microbiology, 1996: 91.
27. Saugier-Veber P, Devergie A, Sulahian A et al. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5-year retrospective study. Bone Marrow Transplant 1993; 12: 121-124.
28. Schaffner A, Böhler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 1993; 36: 421-424.
29. Schiraldi GF, Colombo MD, Harari S. Terbinafine in the treatment of non-immunocompromised compassionate cases of bronchopulmonary aspergillosis. Mycoses 1995; 39: 5-12.
30. Schiraldi GF, Lo Cicero S, Rossato D et al. Terbinafina: un nuovo farmaco antimicotico nel trattamento dell'aspergillosi polmonare. Studio pilota. L'Internista, in press.
31. Schmitt HJ, Bernard EM, Andrade J, Edwards F, Schmitt B, Armstrong D. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 1988; 32: 780-781.
32. Schmitt HJ, Andrade J, Edwards F et al. Inactivity of terbinafine in a rat model of pulmonary aspergillosis. Eur J Clin Microb Infect Dis 1990; 9: 832-835.
33. Sheretz RJ, Belani A, Kramer BS et al. Impact of air filtration on nosocomial aspergillus infections. Am J Med 1987; 83: 709-718.
34. Shuster I. The interaction of representative members from two classes of antimycotics. The azoles and the allylamine with cytochrome P-450 in steroidogenic tissue and liver. Xenobiotica 1985; 15: 529-546.
35. Stark JE. Allergic pulmonary aspergillosis successfully treated with inhalation of nystatin. Dis Chest 1967; 51: 96-99.
36. Stiller MJ, Teperman L, Rosenthal SA et al. Primary cutaneous infection by Aspergillus ustus in a 62-year-old liver transplant recipient. J Am Acad Dermatol 1994; 31: 344-347.
37. Sugar AM. Azole antifungals. In: Sarosi A, Davies SF, eds. Fungal disease of the lung. New York: Raven Press, 1993: 313-322.
38. Tang CM, Holden DW, Aufauvre-Brown A, Cohen J. The detection of Aspergillus spp. by the polymerase chain reaction and its evaluation in bronchoalveolar lavage fluid. Am Rev Respir Dis 1993; 148: 1313-1317.
39. Urbina JA, Lazardi K, Aguirre T, Piras MM, Piras R. Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amasti-gotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 1988; 32: 1237-1242.
40. Vago T, Baldi G, Colombo MD. Effects of naftifine and terbinafine, two allylamine antifungal drugs, on selected functions of human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1994; 38: 2605-2611.
41. Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126: 61-69.
42. Wheat LJ. The role of the serologic diagnostic laboratory and the diagnosis of fungal disease. In: Sarosi A, Davies SF, eds. Fungal disease of the lung. New York: Raven Press, 1993: 29-38.